<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04780074</url>
  </required_header>
  <id_info>
    <org_study_id>TISHCON/CoQ10-01</org_study_id>
    <nct_id>NCT04780074</nct_id>
  </id_info>
  <brief_title>Comparative Single-dose Bioavailability Study of Different CoQ10 Formulations</brief_title>
  <official_title>Comparative Single-dose Bioavailability Study of Different CoQ10 Formulations in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nutrition Institute, Slovenia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vizera d.o.o.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ADM, Ambulanta družinske medicine, Ljubljana, Slovenia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Adrialab d.o.o., Ljubljana, Slovenia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tishcon Corp., USA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nutrition Institute, Slovenia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The single-center, randomized, open-label, five-period crossover single-dose bioavailability&#xD;
      study with five CoQ10 formulations&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The single-center, randomized, open-label, five-period crossover bioavailability study will&#xD;
      include 30 subjects who will test five CoQ10 formulations. Study will be conducted with&#xD;
      single dose CoQ10 to assess bioavailability.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 20, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Five-period crossover bioavailability study will include 30 subjects who will test five CoQ10 formulations. Subjects will test 5 formulations of single dose CoQ10 with 2 week wash-out. to assess bioavailability.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative single dose bioavailability (AUC48) of IP (in comparison to SP)</measure>
    <time_frame>72 hours</time_frame>
    <description>Relative bioavailability between the investigational products and the standard product (IP1 vs. SP, IP2 vs. SP, IP3 vs. SP, and IP4 vs. SP) expressed as ratio of baseline corrected AUC0-72h, i.e. area under the plasma concentration curve from the administration time to the last observation point (72h) of CoQ10 plasma concentrations above the baseline value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative single dose bioavailability (AUCinf) of IP (in comparison to SP)</measure>
    <time_frame>72 hours</time_frame>
    <description>Relative bioavailability between the investigational products and the standard product (IP1 vs. SP, IP2 vs. SP, IP3 vs. SP, and IP4 vs. SP) expressed as ratio of baseline corrected AUCinf, i.e. extrapolated area under the CoQ10 plasma concentration curve above the baseline CoQ10 concentration.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Relative single dose bioavailability (AUC48) among all the investigational products</measure>
    <time_frame>72 hours</time_frame>
    <description>Relative bioavailability among all the investigational products (IP1 vs. IP2, IP1 vs. IP3, IP1 vs. IP4, IP2 vs. IP3, IP2 vs. IP4, and IP3 vs. IP4) expressed as ratio of baseline corrected AUC0-72h, i.e. area under the plasma concentration curve from the administration time to the last observation point (72h) of CoQ10 plasma concentrations above the baseline value.</description>
  </other_outcome>
  <other_outcome>
    <measure>Relative single dose bioavailability (AUCinf) among all investigational products</measure>
    <time_frame>72 hours</time_frame>
    <description>Relative bioavailability among all investigational products (IP1 vs. IP2, IP1 vs. IP3, IP1 vs. IP4, IP2 vs. IP3, IP2 vs. IP4, and IP3 vs. IP4) expressed as ratio of baseline corrected AUCinf, i.e. extrapolated area under the CoQ10 plasma concentration curve above the baseline CoQ10 concentration.</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Bioavailability of Coenzyme Q10</condition>
  <arm_group>
    <arm_group_label>Standard product (SP): USP CoQ10 powder, hard capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 mg per capsule; dosage: 2 capsules - 200 mg total CoQ10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigational product 1 (IP1): CoQ10 in soybean oil, softgels</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg per softgel; dosage: 2 softgels - 200 mg total CoQ10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigational product 2 (IP2): Q-Gel hydrosoluble/bioenhanced CoQ10, softgels</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg per softgel; dosage: 2 softgels - 200 mg total CoQ10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigational product 3 (IP3): Qunol Mega Ubiquinol, softgels</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg per softgel; dosage: 2 softgels - 200 mg total CoQ10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigational product 4 (IP4): HydroQsorb Coenzyme Q10, hard capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg per capsule; dosage: 2 capsules - 200 mg total CoQ10</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Single dose intervention with Standard product (SP)</intervention_name>
    <description>2 capsules - 200 mg total CoQ10</description>
    <arm_group_label>Standard product (SP): USP CoQ10 powder, hard capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Single dose intervention with Investigational product (IP1)</intervention_name>
    <description>2 softgels - 200 mg total CoQ10</description>
    <arm_group_label>Investigational product 1 (IP1): CoQ10 in soybean oil, softgels</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Single dose intervention with Investigational product (IP2)</intervention_name>
    <description>2 softgels - 200 mg total CoQ10</description>
    <arm_group_label>Investigational product 2 (IP2): Q-Gel hydrosoluble/bioenhanced CoQ10, softgels</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Single dose intervention with Investigational product (IP3)</intervention_name>
    <description>2 softgels - 200 mg total CoQ10</description>
    <arm_group_label>Investigational product 3 (IP3): Qunol Mega Ubiquinol, softgels</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Single dose intervention with Investigational product (IP4)</intervention_name>
    <description>2 capsules - 200 mg total CoQ10</description>
    <arm_group_label>Investigational product 4 (IP4): HydroQsorb Coenzyme Q10, hard capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject Informed consent form (ICF) is singed&#xD;
&#xD;
          -  Aged between 18 and 65 years at the time of the signature of ICF&#xD;
&#xD;
          -  A body mass index between 18.5-29.9 kg/m2&#xD;
&#xD;
          -  Total blood cholesterol range 3,11 - 6,50 mmol/L (not treated with medications)&#xD;
&#xD;
          -  Healthy, meaning absence of any prescribed medication for a month prior to the&#xD;
             inclusion to the study and during the study&#xD;
&#xD;
          -  Willing to avoid a consumption of any food supplements except vitamin D and calcium at&#xD;
             least 2 weeks before and during the study&#xD;
&#xD;
          -  Consumption of dairy and cereal products (standardised breakfast will include low&#xD;
             lactose dairy and bread)&#xD;
&#xD;
          -  Willing to follow all study procedures, including attending all site visits (including&#xD;
             sessions during which a venous line will be inserted for blood sampling)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Intake of any prescribed medication within 2 weeks of the beginning of the study&#xD;
&#xD;
          -  Intake of any food supplements within 2 weeks of the beginning of the study, except&#xD;
             vitamin D and calcium&#xD;
&#xD;
          -  Pregnancy or planned pregnancy&#xD;
&#xD;
          -  Breast-feeding mother&#xD;
&#xD;
          -  Hypotension&#xD;
&#xD;
          -  Any clinically significant history of serious digestive tract, liver, kidney,&#xD;
             cardiovascular or haematological disease, diabetes&#xD;
&#xD;
          -  Gastrointestinal disorders or other serious acute or chronic diseases&#xD;
&#xD;
          -  Known lactose/gluten intolerances/ food allergies (limitation for standardisation of&#xD;
             meals)&#xD;
&#xD;
          -  Inadequate veins (in the opinion of the investigator) or known contraindication to&#xD;
             placement of a dedicated peripheral line for venous blood withdrawal&#xD;
&#xD;
          -  Known drug and/or alcohol abuse&#xD;
&#xD;
          -  Using any form of nicotine or tobacco&#xD;
&#xD;
          -  Mental incapacity that precludes adequate understanding or cooperation&#xD;
&#xD;
          -  Participation in another investigational study or blood donation within 3 months prior&#xD;
             to or during this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Igor Pravst</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nutrition Institute, Ljubljana</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tina Modrej Zadnikar</last_name>
    <role>Principal Investigator</role>
    <affiliation>ADM, Ambulanta družinske medicine, Ljubljana, Slovenia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Igor Pravst, PhD</last_name>
    <phone>+386 590 68871</phone>
    <email>igor.pravst@nutris.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>ADM, ambulanta družinske medicine, Ljubljana, Slovenia</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Modrej Zadnikar</last_name>
      <phone>+386 1 422 29 15</phone>
      <email>info@adm.si</email>
    </contact>
    <investigator>
      <last_name>Tina Modrej Zadnikar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 23, 2021</study_first_submitted>
  <study_first_submitted_qc>February 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nutrition Institute, Slovenia</investigator_affiliation>
    <investigator_full_name>Igor Pravst</investigator_full_name>
    <investigator_title>Prof. Dr. Igor Pravst</investigator_title>
  </responsible_party>
  <keyword>coenzyme q10</keyword>
  <keyword>single dose bioavailability</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

